placeholder image
J. Rosenstock All authors
About
Publications While At HealthPartners
selected publications
Journal Article
  • Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. 
    Journal of Diabetes Science and Technology. 2022
  • Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. 
    Diabetes care. 2021
  • Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. 
    Diabetes Technology & Therapeutics. 2019
  • Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. 
    Diabetes care. 2016
  • Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. 
    Journal of Diabetes. 2016
  • Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. 
    Diabetes, Obesity & Metabolism. 2014
  • Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. 
    Diabetes care. 2014
  • Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. 
    Diabetes care. 2013
  • A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. 
    Diabetes care. 2012
  • Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. 
    Diabetes care. 2012
  • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. 
    Annals of Internal Medicine. 2011
  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 
    Lancet (London, England). 2009
  • Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. 
    Diabetes care. 2008
  • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. 
    Diabetes care. 2005
    • Conference Poster
  • Optimizing basal-bolus therapy in T2D—a randomized controlled trial comparing bolus insulin delivery using an insulin patch vs. an insulin pen [poster]
    2018
    • Review
  • Continuous glucose monitoring and metrics for clinical trials: an international consensus statement [review]. 
    The lancet. Diabetes & endocrinology. 2023
    • Abstract
  • Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]. 
    Diabetes. 2016
    • Contact
    full name
  • J. Rosenstock
    • Quick Info
     
    Collaboration